E
Emergo Therapeutics
Emergo is developing treatments to target the release of inflammatory molecules in order to tune down inflammation at its source
About Emergo Therapeutics
Emergo Therapeutics is a biopharmaceutical company focused on developing innovative treatments that target the release of inflammatory molecules, aiming to balance the immune response and reduce inflammation at its source. The company operates in the healthcare and pharmaceutical market, primarily serving patients suffering from conditions related to excessive inflammation. Emergo's business model involves conducting rigorous clinical trials to validate the efficacy and safety of its lead compound, norketotifen, which has shown promise in treating influenza and influenza-like illnesses. The company generates revenue through the development and potential commercialization of its therapeutic solutions, as well as through strategic partnerships and licensing agreements. Emergo has successfully completed Phase 1 and Phase 2a clinical trials and is currently advancing to Phase 2b, demonstrating strong market potential and investor confidence. The company's leadership includes experienced professionals such as Jack Bailey, President of GSK Pharmaceuticals USA, who bring valuable expertise to guide its strategic direction.
Source: Dealroom company dataNews
Open roles
Emergo Therapeutics in the Durham ecosystem
The Emergo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Rex Health Ventures
Series B and later1 investor entered at this stage
North Carolina Biotechnology Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Emergo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emergo Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


